Teva & Celltrion, Amgen & Allergan submit Herceptin biosimilars to FDA
Teva, Celltrion launch Herceptin biosimilar in US - Globes
Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership | World Pharma Today
FDA approves first Rituxan biosimilar courtesy of Teva and Celltrion | Pharmafile
Drama in Teva: Cutting 7,000 jobs in 45 countries ; share price plunges
Teva bolsters its biosimilar business through $160m Celltrion deal
Teva: Migraine Mab Delay After 'Negative Surprise' of Celltrion Warning - BioProcess InternationalBioProcess International
Teva and Celltrion Launch Trastuzumab Biosimilar in U.S. - Big Molecule Watch
Teva, Celltrion get FDA nod for biosimilar to Roche's breast cancer drug
Jobs with Celltrion Healthcare (Formerly Known As Celltrion) | page 2
Teva: 'Celltrion deal will double biosimilar sales to $600m'
Teva highlights fasinumab and biosims as drivers - Bioprocess InsiderBioProcess International
Biosimilars: Celltrion paves way for Herceptin copycats in 2018 - Pharmaceutical Technology
Teva and Celltrion Launch Truxima (biosimilar- rituximab) to Treat Wegener's Granulomatosis and Microscopic Polyangiitis in the US
Teva faces unexpected delay for its migraine drug candidate even as generics pressures worsen | Fierce Pharma
Teva and Celltrion Announce the Availability of TRUXIMA® (rituximab-abbs) Injection, the First Biosimilar to Rituxan® (rituximab) in the United States | Business Wire
Teva and Celltrion Launch Rituximab Biosimilar in US - Big Molecule Watch
Teva: 'Celltrion deal will double biosimilar sales to $600m'
Teva buys US rights to Celltrion biosimilars -
Teva, Celltrion launch their Rituxan biosimilar Truxima | Drug Store News
Celltrion/Teva Rituxan biosimilar edges closer to US approval -
Teva, Celltrion Partner | Technology Networks
Teva and Celltrion Launch Herzuma (biosimilar- trastuzumab) in the US
Truxima Hits 20% Share For Teva :: Generics Bulletin
